Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2016
Volume 2016 eBook
Issue 1
Pages: s46-s54

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.
Articles in this issue
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Optimizing Tablet Compression
Optimizing Tablet Compression
Excipient-Quality-and-Selection.jpg
Excipient Quality and Selection
Pages-from-PTeBook0316_034-038_continuous_freeman.jpg
Filling the Analysis Gap in the Move to Continuous Processing
Pages-from-PTeBook0316_046-054_Generics_DMFs_Subburaj.jpg
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances
Pages-from-PTEBook0316_022-025_Modeling.jpg
Modeling and Simulation Move Downstream
Unifying-Excipient-Databases.jpg
Unifying Excipient Databases
Pages-from-PTeBook0316_020-021_Capsugel.jpg
Establishing a New Performance Standard for HPMC Capsules
Recent Videos
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content
Close up the media plate on hand medical technicians working on bacterial culture and drug resistance of pathogens in laboratory. | Image Credit: © analysis121980 - stock.adobe.com

Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics

Patrick Lavery
June 26th 2025
Article

Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Quattrii Delivers Biologics and mRNA Molecules in Single Inhalation

Susan Haigney
June 25th 2025
Article

Cambridge Healthcare Innovations says its dry powder inhaler engine, Quattrii, can deliver large volumes of biologic and mRNA molecules in a single inhalation.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton
June 24th 2025
Article

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Six Biosimilars Part of EMA’s Authorization Recommendations in June

Susan Haigney
June 23rd 2025
Article

A total of 13 drugs were granted recommendation for market authorization at EMA’s CHMP June 2025 meeting.